Abstract
In this study, thirty-nine sputum samples from tuberculosis (TB)-positive patients undergoing first-line therapy were collected and archived on a chemical-coated cellulose matrix. DNA was extracted from these matrices and tested for Mycobacterium tuberculosis using the Xpert MTB/RIF Ultra assay. Seven samples tested positive for M. tuberculosis, with low levels of detection. End-point PCR yielded faint signals in four samples, but no signal in the remaining three. A Line Probe Assay (LPA) detected pathogen DNA in only one of the three PCR-negative samples. Remarkably, the LPA-negative samples were successfully detected by LPA and end-point PCR following isothermal, strand displacement-based whole genome amplification (WGA) of the stock DNA. The drug sensitivity profile of these samples was consistent with the Xpert MTB/RIF Ultra results obtained from the original stock DNA. Additionally, sputum DNA from healthy individuals spiked with 125 ng, but not with 1.25 ng, of M. tuberculosis culture DNA was detected by LPA. Following WGA, the 1.25 ng sample was also detected successfully by LPA, and its drug sensitivity profile matched that of the 125-ng sample. These findings indicate that WGA of sputum DNA from a cellulose matrix, even with low pathogen load, can enhance the detection capabilities of LPA by enriching the genome target through an isothermal enzymatic strand displacement method. This method holds promise for improving diagnostic sensitivity in TB detection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was partly funded by Grand Challenge-TB Control (GCTBC) grants, namely GCTBC/C2P1/2015/09/30/01 & GCTBC/C2P2/2017/04/01/01 and co-funded by Industry Research Assistance Council (BIRAC) of the Government of India, United States Agency for International Development (USAID), and Bill & Melinda Gates Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Thics committee/IRB of Nirmal Hospital, Sagrampura, Surat, Gujarat 395002 (Ethics committee Approval Number: Nirmal/HPL/Ethics/001) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
